FDA Committees Weigh the Risks and Benefits of Esketamine for TRD (2019)
Introduction: In 2019, the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) evaluated […]
Provider Regulation
FDA Drug Approval: A Guide to Regulatory Milestones and Implications (FDA, 2019)
Introduction: The FDA’s drug approval process ensures that new therapies meet high standards of safety and efficacy before they are
Ketamine and Esketamine Trials for TRD: A Clinical Update (Duke Scholars, January 2023)
Introduction: Ketamine and esketamine are increasingly investigated for their potential in managing TRD. This systematic review examines clinical trials registered
Ketamine and Esketamine: Emerging Indications and Mechanisms, Oct 2024 Review
Introduction The study by Vekhova et al. (Oct 2024) presents a comprehensive review of ketamine and esketamine’s evolving role in
Clinical Trial Insights: Ketamine’s Expanding Role in Psychiatry (Peyrovian et al., 2020)
Introduction: Peyrovian et al.’s 2020 review in the Journal of Psychiatric Research summarizes registered clinical trials evaluating ketamine for psychiatric
Ketamine Pilot Study for Late-Life Depression: Early Insights (Lenze, ClinicalTrials.gov, 2020)
Introduction: Dr. Eric Lenze’s 2020 pilot study investigates ketamine’s safety and efficacy in older adults with treatment-resistant depression (TRD). This
Esketamine: A Paradigm Shift in TRD Treatment (Kim et al., NEJM, 2019)
Introduction: Kim and colleagues’ 2019 article in The New England Journal of Medicine reviews the groundbreaking approval of esketamine as
Esketamine: Insights into a Novel NMDA Antagonist for TRD (Hough, FDA, 2019)
Introduction: Dr. David Hough’s 2019 FDA report presents a comprehensive overview of esketamine, its development, and its approval as a
FDA Committees Weigh the Risks and Benefits of Esketamine for TRD (2019)
Introduction: In 2019, the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) evaluated
Ketamine and Esketamine Trials for TRD: A Clinical Update (Duke Scholars, January 2023)
Introduction: Ketamine and esketamine are increasingly investigated for their potential in managing TRD. This systematic review examines clinical trials registered